In Silico Prediction of Human Bioavailability

[1]  L. A. Fenu,et al.  Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs , 2007, Drug Metabolism and Disposition.

[2]  D. Leahy,et al.  Progress in simulation modelling for pharmacokinetics. , 2003, Current topics in medicinal chemistry.

[3]  M. Andersen.  Physiologically based pharmacokinetic (PB-PK) models in the study of the disposition and biological effects of xenobiotics and drugs. , 1995, Toxicology letters.

[4]  H. van de Waterbeemd,et al.  Property-based design: optimization of drug absorption and pharmacokinetics. , 2001, Journal of medicinal chemistry.

[5]  T. Porter.  Jud Coon: 35 years of p450 research, a synopsis of p450 history. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[6]  P A Kollman,et al.  Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. , 2001, Journal of medicinal chemistry.

[7]  Sean Ekins,et al.  Modeling of active transport systems. , 2002, Advanced drug delivery reviews.

[8]  Han van de Waterbeemd,et al.  Simulation models for drug disposition and drug interactions , 2004 .

[9]  Manfred Kansy,et al.  Predicting plasma protein binding of drugs: a new approach. , 2002, Biochemical pharmacology.

[10]  Johann Gasteiger,et al.  Ligand-Based Models for the Isoform Specificity of Cytochrome P450 3A4, 2D6, and 2C9 Substrates , 2007, J. Chem. Inf. Model..

[11]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[12]  I Moriguchi,et al.  Non-congeneric structure-pharmacokinetic property correlation studies using fuzzy adaptive least-squares: oral bioavailability. , 1994, Biological & pharmaceutical bulletin.

[13]  Arun K Mandagere,et al.  Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. , 2002, Journal of medicinal chemistry.

[14]  Robert D. Clark,et al.  Predicting drug pharmacokinetic properties using molecular interaction fields and SIMCA , 2003, J. Comput. Aided Mol. Des..

[15]  J. Groten,et al.  Predicted serum folate concentrations based on in vitro studies and kinetic modeling are consistent with measured folate concentrations in humans. , 2006, The Journal of nutrition.

[16]  H. van de Waterbeemd,et al.  ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.

[17]  Thomas M. Ludden,et al.  Commentary on “physiologically based pharmacokinetic modeling as a tool for drug development” , 1995, Journal of Pharmacokinetics and Biopharmaceutics.

[18]  Barry C Jones,et al.  Predicting oral absorption and bioavailability. , 2003, Progress in medicinal chemistry.

[19]  Martyn G. Ford,et al.  Simultaneous prediction of aqueous solubility and octanol/water partition coefficient based on descriptors derived from molecular structure , 2001, J. Comput. Aided Mol. Des..

[20]  Yi Han,et al.  Predicting Caco-2 Cell Permeation Coefficients of Organic Molecules Using Membrane-Interaction QSAR Analysis , 2002, J. Chem. Inf. Comput. Sci..

[21]  Marco Pintore,et al.  Prediction of oral bioavailability by adaptive fuzzy partitioning. , 2003, European journal of medicinal chemistry.

[22]  Pierre Bruneau,et al.  Prediction of Physicochemical Properties , 2000 .

[23]  Scott Boyer,et al.  New methods in predictive metabolism , 2002, J. Comput. Aided Mol. Des..

[24]  Ismael Zamora,et al.  Model based on GRID-derived descriptors for estimating CYP3A4 enzyme stability of potential drug candidates , 2004, J. Comput. Aided Mol. Des..

[25]  G. Grass,et al.  Physiologically-based pharmacokinetic simulation modelling. , 2002, Advanced drug delivery reviews.

[26]  S. Ekins,et al.  Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[27]  Han van de Waterbeemd,et al.  Pharmacokinetics and Metabolism in Drug Design: SMITH: PHARMACOKINETICS AND METABOLISM IN DRUG DESIGN O-BK , 2006 .

[28]  Inman Harvey,et al.  Evolutionary computational methods to predict oral bioavailability QSPRs. , 2002, Current opinion in drug discovery & development.

[29]  Rieko Arimoto,et al.  Computational models for predicting interactions with cytochrome p450 enzyme. , 2006, Current topics in medicinal chemistry.

[30]  Chad Stoner,et al.  Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability. , 2006, International journal of pharmaceutics.

[31]  Sean Ekins,et al.  Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. , 2005, Trends in pharmacological sciences.

[32]  S. Venkatesh,et al.  Role of the development scientist in compound lead selection and optimization. , 2000, Journal of pharmaceutical sciences.

[33]  Li Xing,et al.  Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. , 2004, Journal of medicinal chemistry.

[34]  Patrick Poulin,et al.  Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. , 2003, Toxicology letters.

[35]  Lars Carlsson,et al.  State-of-the-art Tools for Computational Site of Metabolism Predictions: Comparative Analysis, Mechanistical Insights, and Future Applications , 2007, Drug metabolism reviews.

[36]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery, 7. Prediction of Oral Absorption by Correlation and Classification , 2007, J. Chem. Inf. Model..

[37]  K. Raghavan,et al.  Predicting Effect of Food on Extent of Drug Absorption Based on Physicochemical Properties , 2007, Pharmaceutical Research.

[38]  Fumiyoshi Yamashita,et al.  In silico approaches for predicting ADME properties of drugs. , 2004, Drug metabolism and pharmacokinetics.

[39]  Panos Macheras,et al.  In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. , 2002, European Journal of Pharmaceutical Sciences.

[40]  Kjell Johnson,et al.  Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery. , 2004, International journal of pharmaceutics.

[41]  Philip Judson,et al.  Predicting Drug Metabolism – An Evaluation of the Expert System METEOR , 2005, Chemistry & biodiversity.

[42]  Lawrence X. Yu,et al.  Predicting Human Oral Bioavailability of a Compound: Development of a Novel Quantitative Structure-Bioavailability Relationship , 2000, Pharmaceutical Research.

[43]  Shobha Bhattachar,et al.  The road map to oral bioavailability: an industrial perspective , 2006, Expert opinion on drug metabolism & toxicology.

[44]  Martin Kuentz,et al.  A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[45]  W. L. Jorgensen,et al.  Prediction of drug solubility from structure. , 2002, Advanced drug delivery reviews.

[46]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[47]  Y. Martin,et al.  A bioavailability score. , 2005, Journal of medicinal chemistry.

[48]  B. Walther,et al.  Rapid assessment of drug metabolism in the drug discovery process. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[49]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[50]  Sanjivanjit K. Bhal,et al.  The Rule of Five revisited: applying log D in place of log P in drug-likeness filters. , 2007, Molecular pharmaceutics.

[51]  Junmei Wang,et al.  Genetic Algorithm-Optimized QSPR Models for Bioavailability, Protein Binding, and Urinary Excretion , 2006, J. Chem. Inf. Model..

[52]  Laszlo Urban,et al.  Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety , 2007, Expert opinion on drug metabolism & toxicology.

[53]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery, 6. Can Oral Bioavailability in Humans Be Effectively Predicted by Simple Molecular Property-Based Rules? , 2007, J. Chem. Inf. Model..

[54]  I. Poggesi,et al.  Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs. , 2006, European journal of medicinal chemistry.

[55]  P N Judson,et al.  Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. , 1999, SAR and QSAR in environmental research.

[56]  Joseph V. Turner,et al.  Prediction of drug bioavailability based on molecular structure , 2003 .

[57]  William J Egan,et al.  Prediction of intestinal permeability. , 2002, Advanced drug delivery reviews.

[58]  T. Kennedy.  Managing the drug discovery/development interface , 1997 .

[59]  T N Thompson,et al.  Early ADME in support of drug discovery: the role of metabolic stability studies. , 2000, Current drug metabolism.

[60]  Ryosei Kawai,et al.  Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125 , 1994, Journal of Pharmacokinetics and Biopharmaceutics.

[61]  D. Livingstone.  Theoretical property predictions. , 2003, Current topics in medicinal chemistry.

[62]  Michael M. Mysinger,et al.  Computational models for cytochrome P450: a predictive electronic model for aromatic oxidation and hydrogen atom abstraction. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[63]  John G. Topliss,et al.  QSAR Model for Drug Human Oral Bioavailability1 , 2000 .

[64]  Adriano D Andricopulo,et al.  Hologram QSAR model for the prediction of human oral bioavailability. , 2007, Bioorganic & medicinal chemistry.

[65]  Terry R Stouch,et al.  Progress in understanding the structure-activity relationships of P-glycoprotein. , 2002, Advanced drug delivery reviews.

[66]  Anders Karlén,et al.  Structural analysis of CYP2C9 and CYP2C5 and an evaluation of commonly used molecular modeling techniques. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[67]  R. Sheridan,et al.  Empirical regioselectivity models for human cytochromes P450 3A4, 2D6, and 2C9. , 2007, Journal of medicinal chemistry.

[68]  Patrizia Crivori,et al.  Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[69]  Yi Li,et al.  In silico ADME/Tox: why models fail , 2003, J. Comput. Aided Mol. Des..

[70]  Brian D. Hudson,et al.  A Consensus Neural Network-Based Technique for Discriminating Soluble and Poorly Soluble Compounds , 2003, J. Chem. Inf. Comput. Sci..

[71]  Joseph V. Turner,et al.  Bioavailability Prediction Based on Molecular Structure for a Diverse Series of Drugs , 2004, Pharmaceutical Research.

[72]  Donald E Mager,et al.  Quantitative structure-pharmacokinetic/pharmacodynamic relationships. , 2006, Advanced drug delivery reviews.

[73]  A. Li,et al.  Screening for human ADME/Tox drug properties in drug discovery. , 2001, Drug discovery today.